PAMA Means Pathology Billing Data Is Now an Asset
3Gen Consulting, Content TeamSeptember 28, 2026
Pathology billing data has become more valuable than ever in the revenue cycle, largely because of changes at the federal level.
The Protecting Access to Medicare Act (PAMA) of 2014 required certain laboratories to report private payor payment rates (in addition to other requirements) for use in determining lab fee schedules. Earlier this year, the Centers for Medicare & Medicaid Services (CMS) began collecting private payor rate data through its Fee-for-Service Data Collection System Clinical Lab Fee Schedule Module (CLFS), which ran from May 1 through July 31, 2026. CMS recently released preliminary calendar year 2027 Medicare clinical laboratory fee schedule payment rates, the first tangible result of the latest PAMA reporting cycle.
These changes impact CLIA-certified independent labs, hospital outreach laboratories, and physician office laboratories billing Medicare Part B and that meet certain revenue thresholds and other requirements. For affected labs, it was an opportunity to ensure their data is appropriately captured in CMS calculations of future Medicare payment amounts, but compliance and representation were only the beginning. Even laboratories that were not subject to PAMA reporting requirements can apply the same data-readiness discipline to reimbursement analytics, payer contracting, and revenue-integrity work. This discipline is the foundation of a data-backed analytics strategy that will undergird revenue cycle health for years.
Committing to this level of reporting turns pathology billing data into a strategic reimbursement asset.
Beyond simple claims adjudication and revenue cycle reporting, PAMA readiness supports payer-intelligence and a revenue-leakage dataset. This type of information is useful for hospitals, health systems, and physician practices regardless of whether they were reporting to CMS. It paints a picture of what each payer reimburses at the lab service level, additionally providing insights around volume and variation. This is critical information for contracting, reimbursement integrity, Medicare-impact forecasting, and service-line reporting.
Ultimately, what CMS has signaled is a push toward reporting precision that informs financial performance. Lab RCM leaders should be ready to respond in kind, even aiming to set standards of data use that exceed CMS. PAMA has been an external signal and encouragement to step into data-backed analytics to uncover and address hidden revenue leaks in the laboratory revenue cycle.
At 3Gen Consulting, we turn decades of laboratory revenue cycle management expertise into assets for revenue cycle leaders invested in strategies for sustainable revenue integrity. Learn how you can take this step while also eliminating manual work today.
Hemant Apte, Chief Executive Officer
Hemant Apte is the Founder and CEO of 3Gen Consulting, a leading healthcare revenue cycle management and technology company serving providers, ACOs, and health plans across the U.S. Since founding 3Gen in 2006, Hemant has guided the company’s evolution from a boutique consulting firm into a data-driven organization at the forefront of AI-powered RCM innovation. With decades of experience in U.S. healthcare operations, Hemant continues to provide thought leadership to clients navigating financial, compliance, and technology challenges in an increasingly value-based care environment.
Is Your Lab Data Revealing Where Revenue Is Being Lost?
See how better visibility can support laboratory RCM performance.
Connect with our experts to:
- Improve visibility into payer reimbursement
- Identify potential revenue leakage
- Strengthen laboratory revenue integrity
Explore our strategic insights & resources
View All ResourcesView All Resources
FAQs
The FAQ section simplifies key information about 3Gen Consulting’s services, helping partners navigate our offerings, methodologies, and value.
Talk to an ExpertTalk to an Expert
PAMA changed how Medicare establishes payment rates for many clinical diagnostic laboratory tests by using private payor rate and volume information reported by applicable laboratories. For pathology billing leaders, the broader implication is that accurate reimbursement data has become increasingly important for both compliance and financial analysis.
Pathology billing data can provide visibility into reimbursement by payer and service, as well as volume and payment variation. That information can support payer contracting, revenue integrity, Medicare-impact forecasting, and service-line analysis.
Lab RCM leaders can use payer-level reimbursement data to compare payment patterns, identify variation, evaluate potential underpayments or revenue leakage, and provide stronger information for contracting and financial planning.
PAMA reinforces the importance of accurate, structured reimbursement data within laboratory revenue cycle management. Even laboratories that were not subject to the latest reporting requirements can apply similar data discipline to improve reimbursement analytics and revenue integrity.
Understanding reimbursement at the laboratory service level gives healthcare organizations greater visibility into how payment varies across payers. That information can help revenue cycle and contracting leaders evaluate existing reimbursement performance and make more informed contracting decisions.
3Gen Consulting supports laboratory revenue cycle management across billing, reimbursement, revenue integrity, and workflow optimization. Our approach helps healthcare organizations improve visibility into financial performance while reducing manual work across the laboratory revenue cycle.